Recommendation ID

Frequency of monitoring:- What is the long-term cost effectiveness, in terms of patient-relevant outcomes including bestcorrected visual acuity and quality of life, of different review frequencies/strategies for people at risk of progression to late AMD (wet active)?

Any explanatory notes
(if applicable)

Why this is important:- There is currently no evidence on the different frequencies for monitoring people with AMD. This means that it is not possible to identify an optimum monitoring strategy for people at different stages of AMD, leading to uncertainty in how to correctly manage treatment for individuals or how to configure eye care services to support patients. A study of the needs of people at risk of progression to late AMD (wet active) to identify the optimum review arrangements would remove
this uncertainty. Trials would need to measure visual outcomes and health service resource use to measure the trade-offs between the optimal management of people at risk of disease progression in relation to the use of resource.

Source guidance details

Comes from guidance
Age-related macular degeneration
Date issued
January 2018

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 31/01/2018